 MOUNTAIN VIEW, Calif., April 21, 2021 GLOBE NEWSWIRE -- NeuroPace, Inc. Nasdaq: NPCE, a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of 17.00 per share. All shares of common stock are being offered by NeuroPace for total gross proceeds of 102 million, before deducting underwriting discounts and commissions and offering expenses. In addition, NeuroPace has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. NeuroPaces common stock is expected to begin trading on the Nasdaq Global Select Market on April 22, 2021, under the ticker symbol NPCE. The offering is expected to close on April 26, 2021, subject to the satisfaction of customary closing conditions. 